Eli Lilly has just dropped a financial bomb that follows about the same storyline as Brock Purdy’s 49’er career: exceeding everyone’s expectations… by alot. See: Stunning Wall Street bro’s, but with dolla’ bills, instead of Kim K’s assets. 

(Source: X) 

In short, Eli Lilly caused a proper boost in the markets and its own stock price after reporting a jaw-dropping $11.3 billion in Q2 revenue, signaling a 36% increase in year-over-year sales. In addition to the impressive 13.40% beat in revenue, Eli Lilly’s earnings per share came in even more heavy (like its consumers), as it annihilated analyst estimates by a cool 41.68%. 

(Source: Barrons) 

This positive showing for Eli Lilly had the company raising their total 2024 sales outlook by an astounding $3 billion, as they now project total sales between $45.5 billion and $46.6 billion. Which pretty much tells investors that its optimism for the upcoming quarter parallels that French Olympic pole vaulter’s newfound confidence. Read: When one door closes, another door opens - from Olympics to Adult Films. 

So given this, what exactly is fueling this fiscal fire for Eli Lilly? Well, it’s zero percent surprising that it all has to do with the gaining popularity of Lilly’s flagship medications for diabetes and obesity: Mounjaro and Zepbound. 

(Source: CNBC) 

For instance, as Ozempic is making people look sicker than they were prior to taking the miracle weight loss drug, Mounjaro stole some of the market share as it raked in $3.09 billion in sales, a threefold increase from last year, while Zepbound—just getting its feet wet in the market—brought home $1.24 billion in the second quarter. 

As expected, these earnings results, followed by the company's $5.3 billion manufacturing agenda in their Indiana plant, led to an explosive 10% jump in stock price. Translation: Investors are eating this up like it's the last slice of pizza at a Weight Watchers meeting.

(Source: Giphy) 

Now, with that said, this also comes after the weighing frustrations of Eli Lilly’s supply chain hiccups that caused mult-month shortages for both Mounjaro and Zepbound. However, to add to the good news, the company also announced that all doses of the two flagship drugs are now available on the FDA’s online database of drug shortages. 

(Source: Bloomberg) 

Meaning, no more waiting in a line that mimics the Eagle’s final “Long Goodbye Tour”. Sure, there might still be some delays at your local pharmacy, but hey, motivation to lose a little weight (and fight diabetes obvi) will have people doing just about anything to get it. 

Which is why when it comes to Eli Lilly, it’s clear the company is likely celebrating a tremendous victory with more room to party going into next quarter. Plus, add the projections that indicate sales topping $40 billion annually by the decade’s end, it’s safe to say some of that weight (from analyst criticism) is off Lilly’s shoulders. 

(Source: Giphy) 

So given all of this, what to do with all this information, you ask? Well, don’t sleep on Eli Lilly. Big Pharma is no doubt a colosseum full of competition and greed, (not to mention about as ethical as a wolf guarding a henhouse), however, with these numbers, Lilly is proving that they can make bank and maybe, just maybe, help a few people along the way. 

At the time of this writing, Eli Lilly is up +5.42% on the day (and up +50.19% YTD).